Sarepta Therapeutics provided $15m in a series A round for the startup, which is working on genetic medicines for rare diseases.
US-based gene therapy startup AavantiBio launched yesterday with $107m in a series A round that included $15m from genetic medicine developer Sarepta Therapeutics.
The round also featured hedge fund sponsor Perceptive Advisors, investment manager RA Capital Management and Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital.
AavantiBio will concentrate on genetic therapeutics for rare diseases and its initial focus is on Friedreich’s Ataxia (FA), an inherited genetic disease that leads to central nervous system and cardiac…
